Actions

The flow cytometric diagnosis of AML: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 8: Line 8:


*Most often in AML useful features of immature cells are ''weak expression of CD45'', and expression of ''CD34'' and/or ''CD117''. However, other markers may be useful (See [[table|Markers used to demonstrate primitive nature in AML]])
*Most often in AML useful features of immature cells are ''weak expression of CD45'', and expression of ''CD34'' and/or ''CD117''. However, other markers may be useful (See [[table|Markers used to demonstrate primitive nature in AML]])
*Note that some cases there may be atypical features where primitive nature is less clear, this generally concerns some monocytic cases or APL (see table for details)
*Note that some cases there may be atypical features where primitive nature is less clear, this generally concerns some monocytic cases or APL, but also in other circumstances (see table [[table|Unusual patterns in acute leukaemia]])
----
----



Revision as of 18:54, 11 December 2023

Acute leukaemia types


In most cases a diagnosis of AML by flow cytometry is relatively straightforward, and can be addressed in a structured manner. The key is to ensure atypical cases are identified and unusual diagnoses are not missed. The workflow here is based on WHO criteria.


Question 1. Do the cells have flow cytometric features that support their primitive nature?
AML M1.png Blast cells typically have "primitive" morphology, the initial procedure is to ensure that the cells also express markers of early differentiation

  • Most often in AML useful features of immature cells are weak expression of CD45, and expression of CD34 and/or CD117. However, other markers may be useful (See Markers used to demonstrate primitive nature in AML)
  • Note that some cases there may be atypical features where primitive nature is less clear, this generally concerns some monocytic cases or APL, but also in other circumstances (see table Unusual patterns in acute leukaemia)

Can we confirm myeloid nature?

  • Typical cases can generally be recognised by (see table for details)
  • Atypical cases can still be identified based on a minimal feature set (see table for details)
  • In unusual cases an extended marker panel may allow lineage assignment (see Table for details)

Are there atypical features?

  • Expected abberency
  • Feature that may give concern